伯基特淋巴瘤-话题@MedSci - 梅斯（MedSci）

#伯基特淋巴瘤#

10篇内容 | 1302人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2238428, encodeId=f84422384282b, content=<a href='/topic/show?id=f92a8602447' target=_blank style='color:#2F92EE;'>#自体造血干细胞移植#</a> <a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=中国多中心研究，CAR-T联合自体移植治疗复发难治伯基特淋巴瘤预后良好, objectType=article, longId=851581, objectId=d68885158194, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240603/1717404247596_5579292.png, objectUrl=/article/show_article.do?id=d68885158194, replyNumber=0, likeNumber=20, createdTime=2024-11-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=d68885158194, moduleTitle=中国多中心研究，CAR-T联合自体移植治疗复发难治伯基特淋巴瘤预后良好, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d68885158194)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2178573, encodeId=09e721e85733f, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=Lancet Haematol：R-CODOX-M/R-IVAC和DA-EPOCH-R治疗方案对新诊断的伯基特淋巴瘤患者的临床研究, objectType=article, longId=807733, objectId=555180e73329, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696890490081_4754896.jpeg, objectUrl=/article/show_article.do?id=555180e73329, replyNumber=0, likeNumber=77, createdTime=2024-01-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=555180e73329, moduleTitle=Lancet Haematol：R-CODOX-M/R-IVAC和DA-EPOCH-R治疗方案对新诊断的伯基特淋巴瘤患者的临床研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=555180e73329)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1571450, encodeId=0a0115e14506a, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=Blood：过去十年伯基特淋巴瘤患者的预后情况, objectType=article, longId=198070, objectId=504f1980e0d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=504f1980e0d7, replyNumber=0, likeNumber=92, createdTime=2020-07-28, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=504f1980e0d7, moduleTitle=Blood：过去十年伯基特淋巴瘤患者的预后情况, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=504f1980e0d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571449, encodeId=eb8d15e14494e, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=Blood：伯基特淋巴瘤亚型的全基因组特征, objectType=article, longId=180398, objectId=fe6c180398c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe6c180398c1, replyNumber=0, likeNumber=106, createdTime=2019-10-04, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe6c180398c1, moduleTitle=Blood：伯基特淋巴瘤亚型的全基因组特征, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe6c180398c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571448, encodeId=9c7615e14483c, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：伯基特淋巴瘤, objectType=article, longId=176496, objectId=03331e6496dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03331e6496dd, replyNumber=0, likeNumber=67, createdTime=2019-07-31, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03331e6496dd, moduleTitle=2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：伯基特淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=03331e6496dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571447, encodeId=79b415e1447f7, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=Blood：在分子上，前体B细胞表型的IG-MYC阳性肿瘤与伯基特淋巴瘤明显不同, objectType=article, longId=150550, objectId=29ed15055028, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ed15055028, replyNumber=0, likeNumber=94, createdTime=2018-10-09, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ed15055028, moduleTitle=Blood：在分子上，前体B细胞表型的IG-MYC阳性肿瘤与伯基特淋巴瘤明显不同, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=29ed15055028)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571446, encodeId=8c2115e144616, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=Blood：如何治疗伯基特淋巴瘤, objectType=article, longId=142743, objectId=87f8142e43d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87f8142e43d4, replyNumber=0, likeNumber=91, createdTime=2018-07-09, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87f8142e43d4, moduleTitle=Blood：如何治疗伯基特淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=87f8142e43d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571445, encodeId=a16c15e144572, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=Lancet：利妥昔单抗加化疗治疗伯基特淋巴瘤成人患者效果较好, objectType=article, longId=66397, objectId=a96d6639e1d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a96d6639e1d, replyNumber=0, likeNumber=77, createdTime=2016-04-13, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a96d6639e1d, moduleTitle=Lancet：利妥昔单抗加化疗治疗伯基特淋巴瘤成人患者效果较好, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a96d6639e1d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571444, encodeId=ac2c15e1444a2, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=NEJM：低强度EPOCH -R方案可有效治疗免疫缺陷伯基特淋巴瘤成人患者, objectType=article, longId=26994, objectId=84d826994ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84d826994ac, replyNumber=0, likeNumber=110, createdTime=2013-11-24, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84d826994ac, moduleTitle=NEJM：低强度EPOCH -R方案可有效治疗免疫缺陷伯基特淋巴瘤成人患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=84d826994ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571443, encodeId=83c915e14431d, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=NEJM:低强度化疗方案对伯基特淋巴瘤有效, objectType=article, longId=26700, objectId=fe0426e0021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe0426e0021, replyNumber=0, likeNumber=81, createdTime=2013-11-21, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe0426e0021, moduleTitle=NEJM:低强度化疗方案对伯基特淋巴瘤有效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe0426e0021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571442, encodeId=b88d15e144213, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=Ann Oncol:CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, objectType=article, longId=3010, objectId=32b2301074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b2301074, replyNumber=0, likeNumber=82, createdTime=2011-08-19, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b2301074, moduleTitle=Ann Oncol:CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=32b2301074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1571441, encodeId=5a7215e1441b2, content=<a href='/topic/show?id=34f7260e798' target=_blank style='color:#2F92EE;'>#伯基特淋巴瘤#</a>, objectTitle=CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, objectType=article, longId=3003, objectId=44713003f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44713003f1, replyNumber=0, likeNumber=79, createdTime=2011-08-19, rootId=0, userName=jichang, userId=e5ce15737303, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44713003f1, moduleTitle=CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=44713003f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伯基特淋巴瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#自体造血干细胞移植# #伯基特淋巴瘤#

中国多中心研究，CAR-T联合自体移植治疗复发难治伯基特淋巴瘤预后良好

2024-11-22发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

Lancet Haematol：R-CODOX-M/R-IVAC和DA-EPOCH-R治疗方案对新诊断的伯基特淋巴瘤患者的临床研究

2024-01-01发表于上海

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

Blood：过去十年伯基特淋巴瘤患者的预后情况

2020-07-28

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

Blood：伯基特淋巴瘤亚型的全基因组特征

2019-10-04

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：伯基特淋巴瘤

2019-07-31

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

Blood：在分子上，前体B细胞表型的IG-MYC阳性肿瘤与伯基特淋巴瘤明显不同

2018-10-09

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

Blood：如何治疗伯基特淋巴瘤

2018-07-09

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

Lancet：利妥昔单抗加化疗治疗伯基特淋巴瘤成人患者效果较好

2016-04-13

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

NEJM：低强度EPOCH -R方案可有效治疗免疫缺陷伯基特淋巴瘤成人患者

2013-11-24

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

NEJM:低强度化疗方案对伯基特淋巴瘤有效

2013-11-21

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

Ann Oncol:CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率

2011-08-19

jichang (审核中...)

前往app查看评论内容

#伯基特淋巴瘤#

CODOX-M/IVAC联合利妥昔单抗降低伯基特淋巴瘤复发率

2011-08-19

科室
- - 订阅+
  - 更多科室
工具
服务